Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Operating Leases (2019 - 2025)

Seres Therapeutics (MCRB) has disclosed Operating Leases for 7 consecutive years, with $72.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 12.52% to $72.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.6 million through Dec 2025, down 12.52% year-over-year, with the annual reading at $72.6 million for FY2025, 12.52% down from the prior year.
  • Operating Leases hit $72.6 million in Q4 2025 for Seres Therapeutics, down from $75.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $107.9 million in Q4 2022 to a low of $9.2 million in Q1 2021.
  • Historically, Operating Leases has averaged $65.4 million across 5 years, with a median of $79.2 million in 2025.
  • Biggest five-year swings in Operating Leases: crashed 36.35% in 2021 and later surged 501.08% in 2022.
  • Year by year, Operating Leases stood at $18.0 million in 2021, then soared by 501.08% to $107.9 million in 2022, then fell by 15.09% to $91.7 million in 2023, then fell by 9.48% to $83.0 million in 2024, then decreased by 12.52% to $72.6 million in 2025.
  • Business Quant data shows Operating Leases for MCRB at $72.6 million in Q4 2025, $75.3 million in Q3 2025, and $78.0 million in Q2 2025.